Top Markets
Coin of the day
Nabriva Therapeutics plc Nabriva Therapeutics plc

Nabriva Therapeutics plc

NBRV
Rank in Stocks #39979
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Share Price
$0.63
Last synced: 2023-08-29
Market Cap
$284.20K
Change (1 day)
-21.25%
Change (1 year)
0.00%
Country
IE
Trade Nabriva Therapeutics plc (NBRV)

Category

Number of shares outstanding for Nabriva Therapeutics plc (NBRV)
Number of shares outstanding as of August 2026: 0
According to Nabriva Therapeutics plc latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Nabriva Therapeutics plc (NBRV) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
- -
CH
- -
KR
0.00 -
BE